Subarachnoid hemorrhage (SAH) is a very important cause of morbidity and unfavourable neurological outcome in patients admitted to intensive care unit. One of the main features of the course of these patients is the onset of a neurogenic fever, defined as an increase of the core body temperature > 38.3°C for 2 consecutive days [1], with onset within 72 hours from the occurrence of the bleeding [2] and which is not correlated with an infection source. Fever occurs in up to 70% of the patients affected by SAH and, among these, in the 50% of cases is not possible to find an infection source [3]. In patients with SAH, neurogenic fever, which is always associated with the presence of blood in the subarachnoid space [3] may favour vasospasm, contributing to worse neurologic outcome [1]. Currently, no treatment showed to be effective in SAH-associated neurogenic fever and, unlike septic fever, it is rarely controlled by treatment with usual antipyretic medications, such as cyclooxygenase-2 (COX-2) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids or acetaminophen [4]. Our knowledge on this topic comes primarily from relatively small studies on animal models, therefore a systematic review pooling the results of such studies is appropriate. The primary aim of this review is to systematically search preclinical studies on neurogenic fever in animal models of SAH reporting data on its pathophysiology and prognostic factors. Secondary aims are: searching data in preclinical studies on the efficacy of any pharmacological therapies for neurogenic fever in animal models of SAH and to identify potential etiopathogenetic targets for future research. References 1. Oliveira-Filho, J., et al., Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome. Neurology, 2001. 56(10): p. 1299-304. 2. Hocker, S.E., et al., Indicators of central fever in the neurologic intensive care unit. JAMA Neurol, 2013. 70(12): p. 1499-504. 3. Fernandez, A., et al., Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology, 2007. 68(13): p. 1013-9. 4. Scaravilli, V., G. Tinchero, and G. Citerio, Fever management in SAH. Neurocrit Care, 2011. 15(2): p. 287-94.